Annual report pursuant to Section 13 and 15(d)

Accrued Liabilities and other Long-Term Liabilities (Schedule of Accrued Expenses and Other Long-Term Liabilities) (Details)

v3.21.1
Accrued Liabilities and other Long-Term Liabilities (Schedule of Accrued Expenses and Other Long-Term Liabilities) (Details) - USD ($)
$ in Thousands
Dec. 31, 2020
Dec. 31, 2019
Accrued expenses:    
Professional fees $ 1,236 $ 1,153
Salaries, bonus and related benefits 6,701 6,683
Research and development 5,007 4,215
Research and development - manufacturing 518 1,017
Research and development - license maintenance fees 461 361
Research and development - milestones 600 0
Accrued royalties payable 2,682 2,320
Accrued coupon expense 10,869 8,391
Other 1,188 1,259
Total accrued expenses 29,262 25,399
Other long-term liabilities:    
Deferred rent and long-term lease abandonment charge 1,949 2,136
Partner company note payable, long-term 7,359 4,990
Total other long-term liabilities and partner company note payable, long-term 9,308 7,126
Ximino [Member]    
Other long-term liabilities:    
Partner company note payable, long-term 3,622 4,990
Oral Acne Product (Isotretinoin) [Member]    
Other long-term liabilities:    
Partner company note payable, long-term 2,792 0
Anti-itch Product [Member]    
Other long-term liabilities:    
Partner company note payable, long-term $ 945 $ 0